Angiotensin receptor blockers for heart failure
81 results
1 - 81
Angiotensin receptor blockers for heart failure 
Angiotensin receptor blockers for heart failure Stable (no update expected for reasons given in 'What's new')- Nurse‐led titration of angiotensin converting enzyme inhibitors, beta‐adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction Edited (no change to conclusions)
- Chronic heart failure
- LCZ696 (sacubitril/valsartan) for patients with heart failure New
- Heart failure nurse-led titration of heart failure medicines
- Beta‐blockers and inhibitors of the renin‐angiotensin aldosterone system for chronic heart failure with preserved ejection fraction New search for studies and content updated (conclusions changed)
- Drugs for chronic heart failure with preserved ejection fraction
ACE inhibitors decrease cardio events in patients with diabetes, ARBs don't- ACE inhibitor preferred over ARB in patients with ischemic heart disease
- Angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients Edited (no change to conclusions), comment added to review
- Hypertrophic cardiomyopathy
- Valsartan/sacubitril reduces mortality more than enalapril 10 mg twice daily in patients with heart failure (PARADIGM-HF)
- Calcium channel blockers versus other classes of drugs for hypertension New search for studies and content updated (conclusions changed)
- First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension: Cochrane systematic review
- Guideline for the management of heart failure: early prevention for patients at risk, quadruple therapy for those with symptoms
- Diagnosing and managing acute heart failure Guidelines: NICE
- Drug treatment for hypertension
- Renin angiotensin system inhibitors not useful for CAD without CHF
- Choosing prophylactic medication for atrial fibrillation - Image
- Dilated cardiomyopathy
- Choice of prophylactic medication for atrial fibrillation - Image
- Eplerenone reduces mortality in NYHA II heart failure
- ARB treatment of high CV risk patients
- Digitalis for treatment of heart failure in patients in sinus rhythm: Cochrane systematic review
- ACE inhibitor + ARB = no benefit and increased risk
- First-line renin angiotensin system inhibitors versus other drug classes for hypertension
- Hypertension in elderly patients
- Beta‐blockers in patients without heart failure after myocardial infarction
- ARBs & ACE inhibitors prevent A fib
- Pharmacological interventions for heart failure in people with chronic kidney disease New
- No improved patient-oriented outcomes with sacubitril/valsartan in adults with heart failure and preserved EF (PARALLAX)
- Antihypertensive agents for preventing diabetic kidney disease
- Acute coronary syndrome and myocardial infarction
- Compliance with heart failure performance measures not associated with improved outcomes
- Finerenone decreases hospitalization for heart failure in patients with type 2 diabetes and chronic kidney disease (NNT = 189/year)
- Rhythm control no better than rate control in AF + CHF
- Aldosterone receptor antagonists spironolactone and eplerenone for congestive heart failure
- Perioperative angiotensin‐converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults Edited (no change to conclusions)
- ACE = ARB for secondary CV prevention; combination worse (ONTARGET)
- Acute kidney injury
- ACE inhibitors and angiotensin II receptor blockers for diabetics with microalbuminuria
- Bedtime instead of morning ingestion of hypertension meds = significantly more reduction in cardiovascular disease risk
- ACE inhibitors and angiotensin receptor blockers for progression of non-diabetic renal disease
- Different antihypertensive agents as first line therapies
- Choice of antihypertensive drug in the diabetic patient from prognostic point of view
- JNC 8 report on prevention/evaluation/treatment of hypertension
- Effect of antihypertensive drugs on mortality, morbidity and blood pressure in blacks: Cochrane systematic review
- Finerenone reduces composite cardiovascular outcome and risk of decreased eGFR, but increases risk of hyperkalemia
- Ventricular tachycardia
- Antihypertensive therapy beneficial for patients with BP < 140/90 and history of CVD
- Spironolactone most effective add-on for patients with resistant hypertension (PATHWAY-2)
- Dapagliflozin reduces mortality and renal replacement in patients with chronic kidney disease
- Reporting estimated glomerular filtration rate (GFR) may not improve outcomes
- Secondary hypertension
- Irbesartan slows aortic dilation, but doesn't reduce the rate of surgery in those with Marfan syndrome (AIMS)
- Leg oedema
- SBP of 120 instead of 140 in nondiabetic, high-risk elderly leads to significant benefits and some harms (SPRINT)
- The most common types of acquired adult valvular heart disease and associated murmurs
- Natriuretic peptide‐guided treatment for the prevention of cardiovascular events in patients without heart failure Edited (no change to conclusions)
- BP target of 120 no better than 140 in T2DM (ACCORD)
- Optimal medical tx = PCI + optimal medical tx for stable CAD
- Use of medication during pregnancy